CrossAmerica Partners (NYSE:CAPL – Get Free Report) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued on Wednesday.
CrossAmerica Partners Stock Performance
Shares of CrossAmerica Partners stock opened at $20.74 on Wednesday. The company has a debt-to-equity ratio of 250.71, a current ratio of 0.76 and a quick ratio of 0.37. The firm has a market cap of $788.68 million, a price-to-earnings ratio of 34.00 and a beta of 1.51. CrossAmerica Partners has a one year low of $18.43 and a one year high of $24.19. The stock’s 50-day moving average is $20.04 and its 200-day moving average is $20.80.
CrossAmerica Partners (NYSE:CAPL – Get Free Report) last released its earnings results on Wednesday, August 7th. The oil and gas company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.06 by $0.10. The firm had revenue of $1.13 billion for the quarter, compared to analysts’ expectations of $1.27 billion. CrossAmerica Partners had a negative return on equity of 314.20% and a net margin of 0.51%. Equities analysts predict that CrossAmerica Partners will post 0.46 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
CrossAmerica Partners Company Profile
CrossAmerica Partners LP engages in the wholesale distribution of motor fuels, operation of convenience stores, and ownership and leasing of real estate used in the retail distribution of motor fuels in the United States. It operates in two segments, Wholesale and Retail. The Wholesale segment engages in the wholesale distribution of motor fuels to lessee dealers, independent dealers, commission agents, and company operated retail sites.
Featured Stories
- Five stocks we like better than CrossAmerica Partners
- What is the FTSE 100 index?
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Stock Average Calculator
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Roth IRA Calculator: Calculate Your Potential Returns
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for CrossAmerica Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CrossAmerica Partners and related companies with MarketBeat.com's FREE daily email newsletter.